Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
JCO Glob Oncol ; 9: e2200377, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-37216624

RESUMEN

To describe the population with early malignant melanoma, we performed a cohort study on the basis of the Epidemiological Registry of Malignant Melanoma in Colombia-Asociacion Colombiana de Hematologia y Oncologia. From January 2011 until December 2021, 759 patients were included; the average age was 66 years, 57% were women, acral lentiginous histology was found in 27.8% of patients, and the median follow-up was 36.5 months. The prognostic factors for overall survival in our population are Eastern Cooperative Oncology Group 3-4 (hazard ratio [HR], 13.8), stage III (HR, 5.07), received radiotherapy (HR, 3.38), ulceration on histology (HR, 2.68), chronic sun exposure (HR, 2.3), low income (HR, 2.04), previous local surgery (HR, 0.27), and have received adjuvant treatment (HR, 0.41).


Asunto(s)
Melanoma , Humanos , Femenino , Anciano , Masculino , Estudios de Cohortes , Pronóstico , Colombia/epidemiología , América Latina , Melanoma/diagnóstico , Melanoma/epidemiología , Melanoma/terapia , Sistema de Registros , Melanoma Cutáneo Maligno
2.
Oncologist ; 26(10): e1761-e1773, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34132449

RESUMEN

INTRODUCTION: The ACHOCC-19 study was performed to characterize COVID-19 infection in a Colombian oncological population. METHODOLOGY: Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression. RESULTS: The study included 742 patients; 72% were >51 years. The most prevalent neoplasms were breast (132, 17.77%), colorectal (92, 12.34%), and prostate (81, 10.9%). Two hundred twenty (29.6%) patients were asymptomatic and 96 (26.3%) died. In the bivariate descriptive analysis, higher mortality occurred in patients who were >70 years, patients with lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute-phase reactants. In the logistic regression analysis, higher mortality was associated with Eastern Cooperative Oncology Group performance status (ECOG PS) 3 (odds ratio [OR] 28.67; 95% confidence interval [CI], 8.2-99.6); ECOG PS 4 (OR 20.89; 95% CI, 3.36-129.7); two complications from COVID-19 (OR 5.3; 95% CI, 1.50-18.1); and cancer in progression (OR 2.08; 95% CI, 1.01-4.27). In the Cox regression analysis, the statistically significant hazard ratios (HR) were metastatic disease (HR 1.58; 95% CI, 1.16-2.16), cancer in progression (HR 1.08; 95% CI, 1.24-2.61) cancer in partial response (HR 0.31; 95% CI, 0.11-0.88), use of steroids (HR 1.44; 95% CI, 1.01-2.06), and use of antibiotics (HR 2.11; 95% CI, 1.47-2.95). CONCLUSION: In our study, patients with cancer have higher mortality due to COVID-19 infection if they have active cancer, metastatic or progressive cancer, ECOG PS >2, and low socioeconomic status. IMPLICATIONS FOR PRACTICE: This study's findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired Eastern Cooperative Oncology Group status to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment.


Asunto(s)
COVID-19 , Neoplasias Pulmonares , Estudios de Cohortes , Humanos , América Latina , Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/epidemiología , Masculino , SARS-CoV-2
3.
Rev. colomb. cancerol ; 17(1): 18-24, ene.-mar. 2013. ilus, tab
Artículo en Español | LILACS | ID: lil-729550

RESUMEN

Objetivos: Describir las características sociodemográficas y clínicas de un grupo de pacientes con cáncer de recto localmente avanzado, tratados con quimiorradioterapia neoadyuvante, y realizar un diagnóstico situacional del manejo. Métodos: Se realizó un estudio tipo series de casos, con la información clínica de 41 pacientes atendidos durante el 2010 en el instituto nacional de Cancerología. Resultados: la edad promedio de los pacientes observados fue de 61 años, con un el 61% de hombres; el estado funcional por Karnofsky fue igual o mayor que el 70%. El esquema neoadyuvante más utilizado fue 5 fluorouracilo y leucovorín en bolos, concomitante con radioterapia. De los pacientes, 30 completaron el tratamiento con buena tolerancia; 21 fueron llevados a cirugía, con preservación del esfínter en 10 de ellos; 18 lograron respuesta patológica; 14, parcial y 4, completa. Conclusión: los pacientes con cáncer de recto localmente avanzado que recibieron tratamiento neoadyuvante con quimiorradioterapia en el Instituto Nacional de Cancerología durante 2010 fueron, en su mayoría, hombres con buen estado funcional; el principal esquema de quimioterapia empleado fue 5 fluorouracilo y leucovorín en bolos, gracias a lo cual se logró resecabilidad del tumor, preservación del esfínter y respuesta patológica en aproximadamente la mitad de los pacientes.


Objectives: To describe the sociodemographic and clinical characteristics of a group of patients with locally advanced rectal cancer treated with neoadjuvant chemo-radiotherapy, and to make a situational diagnosis of the management. Methods: A case series study was conducted using the clinical information of 41 patients treated in the Instituto Nacional de Cancerología during the year 2010. Results: The mean age of the patients studied was 61 years, and 60% were male. The Karnofsky functional state was equal or greater than 70%. The neoadjuvant scheme most used was 5-fluorouracil and leucovorin in boluses, concomitant with radiotherapy. Of the 41 patients, 30 completed the treatment with good tolerance; 21 required surgery, with preservation of the sphincter in 10 of them; 18 achieved a pathological response; 14, partial and 4, complete. Conclusion: The patients with locally advanced rectal cancer who received neoadjuvant treatment with chemo-radiotherapy in the Instituto Nacional de Cancerología during the year 2010 were, mainly males with a good functional state. The principal chemotherapy scheme employed was 5-fluorouracil and leucovorin in boluses, due to which resectability of the tumour, preservation of the sphincter, and a pathological response in approximately half of the patients, was achieved.


Asunto(s)
Humanos , Neoplasias del Recto , Terapia Neoadyuvante , Fluorouracilo , Tolerancia , Cirugía General , Terapéutica , Estado , Métodos
4.
Rev. colomb. cancerol ; 16(2): 119-129, jun. 2012. tab
Artículo en Español | LILACS | ID: lil-662991

RESUMEN

El carcinoma córtico-adrenal es una entidad que se presenta raras veces; su evolución es agresiva, con una alta probabilidad de recaída y una supervivencia a 5 años que no supera el 60%. El único tratamiento curativo es la cirugía, siempre y cuando esta sea completa y a los pacientes se los diagnostique en estadios tempranos. Otras intervenciones que se pueden brindar son la radioterapia, la quimioterapia y el control de secreción hormonal en el contexto adyuvante o paliativo. En algunos casos (síndrome de Cushing) el bloqueo hormonal previo a la cirugía es imperativo. En esta revisión se describen la patogénesis, el diagnóstico, los factores pronósticos y el tratamiento del carcinoma córtico-adrenal, con el propósito de guiar el enfoque diagnóstico y el tratamiento.


Adrenal-cortical carcinoma is a rarely occurring entity; it evolves aggressively, has a high probability of relapse and survival at 5 years does not surpass 60%. Surgery provides the only curative treatment, but only when it is complete and carried out on patients with early-stage diagnosis. Additional treatments that may be used include radiotherapy, chemotherapy and control of hormonal secretion in an adjuvant or palliative context. In some cases (Cushing´s syndrome), it is imperative to provide hormonal block before surgery. The pathogenesis, diagnosis, prognostic factors and treatment of adrenal-cortical carcinoma are described in this review in order to sharpen the focus on diagnosis and treatment.


Asunto(s)
Humanos , Carcinoma Corticosuprarrenal , Síndrome de Cushing , Metástasis de la Neoplasia , Cirugía General/métodos
5.
Lung Cancer ; 77(2): 469-72, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22534670

RESUMEN

The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Complicaciones Neoplásicas del Embarazo/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Quinazolinas/uso terapéutico , Adenocarcinoma/diagnóstico , Adenocarcinoma/genética , Adulto , Secuencia de Bases , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/genética , Clorhidrato de Erlotinib , Femenino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/genética , Mutación , Metástasis de la Neoplasia , Embarazo , Complicaciones Neoplásicas del Embarazo/diagnóstico , Resultado del Embarazo , Resultado del Tratamiento
6.
Rev. colomb. cancerol ; 16(1): 49-58, mar. 2012. graf
Artículo en Español | LILACS | ID: lil-662982

RESUMEN

El hemangiosarcoma cutáneo es una enfermedad maligna rara de origen vascular, y corresponde a menos del 1% de todas las malignidades y al 2% de todos los sarcomas de tejidos blandos. Su presentación usual es en el rostro y en la región del cuero cabelludo; al momento de diagnosticarse ya es una enfermedad avanzada. Afecta a menudo al anciano del género masculino y de raza blanca. El tratamiento oncológico se basa en la resección quirúrgica, la radioterapia y la quimioterapia, dado el alto riesgo tanto de recaída local como de diseminación hematológica con intención paliativa. Las tasas de control locorregional a 5 años son, aproximadamente, del 40% al 50%, las tasas de supervivencia libre de metástasis a distancia a 5 años están en el rango del 20% al 40%, y las tasas de supervivencia a 5 años se encuentran entre el 10% y el 30%.


Cutaneous hemangiosarcoma is a rare malignant disease of vascular origin which accounts for less than 1% of all malignancies and 2% of all soft tissue sarcomas. It most frequently affects elderly white males, and is usually found on the face and scalp; at diagnosis it tends to be advanced. Oncologic treatment is based upon surgical resection, radiotherapy and chemotherapy due to the high risk of local relapse as well as to hematologic dissemination with palliative intention. Loco-regional control rates at 5 years range from 40% to 50%, metastasis-free survival rates at 5 years are from 20% to 40%, and survival rates at 5 years from 10% to 30%.


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Biología Molecular/clasificación , Biología Molecular/métodos , Hemangiosarcoma , Neoplasias Cutáneas , Quimioterapia/métodos , Radioterapia/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA